New large-study data show improvements in Grail’s Galleri multi-cancer screening test as the company moves toward broader regulatory review. Results from the PATHFINDER 2 U.S. study—presented at ESMO and reported by STAT and Endpoints—found a sensitivity of 40.4% for cancers in screened adults over 50 and a positive predictive value near 62% among positive tests. The dataset included nearly 36,000 participants and identified cancers not covered by standard screening programs, including pancreatic and liver tumors. Investigators and company analysts note the better-than-earlier performance but stress that unanswered questions remain about downstream diagnostic pathways, overdiagnosis and real-world screening logistics.